Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
List view / Grid view
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
A previously unknown process by which pathogens breach immune defences offers promise for treating infectious diseases.
A new approach called reverse metabolomics has discovered molecules that may serve as a biomarker or a therapeutic target for IBD.
Researchers, using high-resolution mapping and mathematical modelling, have found mechanisms controlling mutation-driven diseases.
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
Findings about how erythrocytes interact with brain capillaries offers new potential treatments for brain microhaemorrhages.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
A signalling mechanism for ventricular fibrillation involving the stress kinases p38γ and p38δ has been discovered.
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline…
In Alzheimer’s disease patients, irritability and anxiety is likely caused by neuroinflammation, which indicates new therapeutic pathways.
Treating C. elegans with inhibitors of small or large mitochondrial ribosomes extended their median lifespan.
Researchers have completely decoded the human Y chromosome, which may result in more effective treatment for digestive disorders.